ACLX
ACLX clinical trials: Arcellx, Inc.
Every trial on ClinicalTrials.gov where Arcellx, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 0
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ACLX on the catalyst calendar · ACLX registry changes
- Primary completion Oct 2026Sponsor estimatePhase 1NCT05457010Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic...Kite, A Gilead Company · Acute Myeloid LeukemiaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 3NCT06413498A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaKite, A Gilead Company · Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Kite, A Gilead Company · Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 3, 2024ActualPhase 1NCT04155749Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaKite, A Gilead Company · Relapsed and Refractory Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner